Adjuvant therapy for early breast cancer: where do we stand today?
Pritchard
Kathleen I
KI
Department of Medicine, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D017024:Chemotherapy, Adjuvant / Q000639:trends; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000276:immunology; D005260:Female; D006801:Humans; D009367:Neoplasm Staging / Q000592:standards / Q000639:trends; D018739:Oncogene Proteins v-erbB / Q000276:immunology; D012307:Risk Factors; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018739:Oncogene Proteins v-erbB; D066246:ErbB Receptors; D000068878:Trastuzumab